Last $17.87 USD
Change Today -0.01 / -0.06%
Volume 1.2M
VOLC On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 2:11 PM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

volcano corp (VOLC) Snapshot

Open
$17.85
Previous Close
$17.88
Day High
$17.88
Day Low
$17.85
52 Week High
03/19/14 - $24.62
52 Week Low
11/10/14 - $9.81
Market Cap
922.2M
Average Volume 10 Days
10.5M
EPS TTM
$-0.74
Shares Outstanding
51.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VOLCANO CORP (VOLC)

volcano corp (VOLC) Related Businessweek News

No Related Businessweek News Found

volcano corp (VOLC) Details

Volcano Corporation designs, develops, manufactures, and commercializes a suite of precision guided therapy tools worldwide. The company operates in two segments, Medical and Industrial. It offers intravascular ultrasound (IVUS) and fractional flow reserve (FFR) products that enhance the diagnosis and treatment of coronary and peripheral vascular disease by enhancing the efficiency and efficacy of existing diagnostic angiograms and percutaneous coronary interventional and endovascular procedures in the coronary arteries or peripheral arteries and veins. The company’s IVUS products include single-procedure disposable phased array and rotational IVUS imaging catheters; and ChromaFlo stent apposition analysis technology that uses sequential IVUS frames to differentiate circulating blood from stationary or anchored tissue. Its FFR products comprise pressure and flow consoles, and single-procedure disposable pressure and flow guide wires, which are used to measure the pressure and flow characteristics of blood around plaque enabling physicians to gauge the plaque’s physiological impact on blood flow and pressure. In addition, the company offers adenosine-free Instant Wave-Free Ratio FFR; and SyncVision, which co-registers IVUS with angiography. Further, the company develops and manufactures optical monitors for the telecommunication industry; laser and non-laser light sources; optical engines used in the medical optical coherence topography imaging systems and advanced photonic components; and sub-systems used in spectroscopy and other industrial applications. It sells its products through direct sales force and distributors, as well as through supply and distribution agreements with third parties. Volcano Corporation was founded in 2000 and is headquartered in San Diego, California.

1,800 Employees
Last Reported Date: 02/28/14
Founded in 2000

volcano corp (VOLC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $638.5K
Chief Finance Officer and Principal Accountin...
Total Annual Compensation: $381.3K
Executive Vice President of Strategy, Busines...
Total Annual Compensation: $358.0K
Compensation as of Fiscal Year 2013.

volcano corp (VOLC) Key Developments

Volcano Corporation Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 09:30 AM

Volcano Corporation Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 09:30 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: R. Scott Huennekens, Chief Executive Officer, President and Director.

Volcano Corporation Reports Unaudited Consolidated Earnings Results for the Third Quarter and First Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Fourth Quarter of 2014; Revises Earnings Guidance for the Full Year 2014

Volcano Corporation reported unaudited consolidated earnings results for the third quarter and first nine months ended September 30, 2014. For the quarter, the company reported revenues of $97.457 million against $95.809 million a year ago. Operating loss was $4.914 million against $6.44 million a year ago. Loss before income tax was $11.971 million against $12.848 million a year ago. Net loss was $8 million or $0.16 basic and diluted per share against $8.456 million or $0.15 basic and diluted per share a year ago. Non-GAAP net loss was $9.499 million or $0.04 loss per share a year ago. The results for the third quarter of 2014 included amortization of intangibles of $2.8 million and restructuring benefits of $229,000 while the results for the third quarter of 2013 included amortization of intangibles of $834,000 and restructuring charges of $4.6 million. For the nine months, the company reported revenues of $294.59 million against $290.384 million a year ago. Operating loss was $6.124 million against $8.342 million a year ago. Loss before income tax was $26.888 million against $24.161 million a year ago. Net loss was $18.622 million or $0.36 basic and diluted per share against $14.005 million or $0.26 basic and diluted per share a year ago. Net cash used in operating activities was $5.610 million against net cash provided by operating activities of $9.041 million a year ago. Purchase of short-term and long-term available-for-sale securities was $161.882 million against $342.715 million a year ago. Capital expenditures were $22.854 million against $26.533 million a year ago. Cash paid for intangible assets and other investments was $4.987 million against $2.377 million a year ago. Non-GAAP net loss was $17.629 million or $0.14 loss per share a year ago. On a constant currency basis, revenues increased 3% year-over-year after adjusting for a negative impact of approximately $3.4 million from foreign currency. Revenue performance in the third quarter and first 9 months of 2014 included: Peripheral IVUS revenues in the U.S. increased approximately 60% in the quarter, with the growth split equally between peripheral imaging catheters and Pioneer sales; FM disposable revenues in Japan increased 23% year-over-year during the quarter. For the fourth quarter, the company expects GAAP net loss per share--basic from $0.15 to $0.17 and non-GAAP net loss per share--basic from $0.03 to $0.05 per share. For the full year 2014, on a GAAP basis, the company expects a loss per share for the full year of $0.50 to $0.52 versus prior guidance for net loss per share on a GAAP basis of $0.52 to $0.55. On a non-GAAP basis, the company expects a loss of $0.16 to $0.18 per share. This compares to guidance of non-GAAP loss per share of 17% to 19%, that's prior guidance. The company expects revenues will be in the range of $393.0-$397.0 million. The company expects gross margins will be 63.0-63.5% and that operating expenses, including restructuring charges, will be 65.0-66.0% of revenues and expects effective tax rate of 35% for the GAAP to non-GAAP adjustments.

Volcano Corporation Presents at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum, Nov-20-2014 03:00 PM

Volcano Corporation Presents at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum, Nov-20-2014 03:00 PM. Venue: The Westin Grand Central, New York, New York, United States. Speakers: John T. Dahldorf, Chief Finance Officer and Principal Accounting Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VOLC:US $17.87 USD -0.01

VOLC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ABIOMED Inc $37.93 USD +1.22
Analogic Corp $86.89 USD +0.39
Cardiovascular Systems Inc $30.07 USD -0.29
Ion Beam Applications €14.55 EUR +0.35
Quidel Corp $28.03 USD +0.395
View Industry Companies
 

Industry Analysis

VOLC

Industry Average

Valuation VOLC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.3x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VOLCANO CORP, please visit www.volcanocorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.